A new clinical unit of QUINTA – ANALYTICA was officially opened in the city center of Ostrava.

The opening ceremony was attended by the company’s management, representatives of the city, deputies of hospitals of Ostrava, and health care experts. In addition to the ribbon-cutting ceremony and a tour of the new facility, the opening ceremony included a discussion among our guests on the topic of clinical trial preparation and the shortage of certain medicines in the Czech Republic.

The clinical unit in Ostrava is intended for clinical trials with healthy volunteers, which will lead to improved availability of medicines for the general public. Clinical trials will be carried out in Ostrava in a similar way to those conducted in the QUINTA-ANALYTICA clinic in Prague for the last two decades.

As part of its collaboration with the City Hospital Ostrava (MNO), the company made a financial donation in the amount of CZK 50,000 (EUR 2 000) to fully equip the waiting room of the Pediatric Department and purchase 3D virtual reality glasses that are used for invasive or traumatic procedures of pediatric patients.

Roman Grunt, CEO of QUINTA-ANALYTICA said:

The opening of the new clinic is our response to the growing demands of customers in clinical trials. After searching for a suitable location, Ostrava was the best choice for us. We are convinced that the region has the necessary qualified professionals who can not only ensure the operation of the new unit, but also provide first-class professional services which our clients from around the globe require.”

 

 

We would like to express our best wishes for the success of the clinic!

 

 

Please follow our social media pages, where we will be gradually publishing more news and a recording of the debate with our guests.

Additional News

  • 15 July 2026

    Quinta-Analytica Awarded the EcoVadis Gold Medal

    Quinta-Analytica has been awarded the EcoVadis Gold Medal after achieving an overall sustainability score of 84 out of 100. The result represents a substantial increase from 68 points in the previous assessment and places the company in the 97th percentile globally.

  • 16 April 2026

    Expanding Beyond FDA & EMA: Strengthening Our Global Regulatory Footprint with GCC

    Quinta-Analytica has successfully completed a full on-site GCP inspection within the GCC framework, further strengthening its international regulatory footprint and clinical research credibility.

  • 25 March 2026

    ADC Webinar: DAR, Bioanalysis and Intact MS in Next-Generation ADC Development

    On behalf of Conscio Group, registration is now open for our free expert-led webinar on DAR characterization, bioanalytical strategy and mass spectrometry insight in ADC development.